Compare Align Technology, Inc. (ALGN) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Canopy Growth Corp — how do they compare? Align Technology, Inc. trades at $174.12 (market cap $12.29B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: Align Technology, Inc. is far larger — about 29.2× Canopy Growth Corp's market cap, and Align Technology, Inc. is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ALGN | CGC | |
|---|---|---|
Market Cap | $12.29B | $421.10M |
Sector | Health | Health |
52-Week High | $197.51 | $1.92 |
52-Week Low | $124.88 | $0.86 |
Enterprise Value | $11.30B | $378.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $173.4, down 1.5% today, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 30.03, and a net income margin of 9.99%. Recent news highlights a patent win in China and strategic initiatives under activist investor engagement, supporting its digital orthodontics leadership.
Outlook remains positive due to solid profitability and growth initiatives, but risks include competitive pressures and scanner segment weakness. Analyst consensus is strongly bullish with 73% buy ratings, viewing current valuation as attractive for long-term growth despite near-term technical headwinds.
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
